Arcutis Biotherapeutics, Inc.
0 products tracked · names used in filings: Arcutis Biotherapeutics, Inc.
Upcoming milestones
ZORYVE cream 0.05%: PDUFA target action date (mild to moderate atopic dermatitis in infants aged 3 to 24 months)
Arcutis Biotherapeutics, Inc. (ARQT); roflumilast; sNDA; status: set; "…FDA accepted sNDA for ZORYVE cream 0.05% to expand indication to include infants with mild to moderate atopic dermatitis aged 3 to 24 months and set target action date of February 23, 2027 • Completed enrollment of the Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo with disclosure of topline"; filed 2026-08-05 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.